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AbsTrACT
Health workers in low- resource settings often lack the 
support and tools to follow evidence- based clinical 
recommendations for diagnosing, treating and managing sick 
patients. Digital technologies, by combining patient health 
information and point- of- care diagnostics with evidence- 
based clinical protocols, can help improve the quality of care 
and the rational use of resources, and save patient lives. 
A growing number of electronic clinical decision support 
algorithms (CDSAs) on mobile devices are being developed 
and piloted without evidence of safety or impact. Here, we 
present a target product profile (TPP) for CDSAs aimed at 
guiding preventive or curative consultations in low- resource 
settings. This document will help align developer and 
implementer processes and product specifications with the 
needs of end users, in terms of quality, safety, performance 
and operational functionality. To identify the characteristics 
of CDSAs, a multidisciplinary group of experts (academia, 
industry and policy makers) with expertise in diagnostic 
and CDSA development and implementation in low- income 
and middle- income countries were convened to discuss a 
draft TPP. The TPP was finalised through a Delphi process 
to facilitate consensus building. An agreement greater than 
75% was reached for all 40 TPP characteristics. In general, 
experts were in overwhelming agreement that, given that 
CDSAs provide patient management recommendations, the 
underlying clinical algorithms should be human- interpretable 
and evidence- based. Whenever possible, the algorithm’s 
patient management output should take into account pretest 
disease probabilities and likelihood ratios of clinical and 
diagnostic predictors. In addition, validation processes should 
at a minimum show that CDSAs are implementing faithfully 
the evidence they are based on, and ideally the impact on 
patient health outcomes. In terms of operational needs, 
CDSAs should be designed to fit within clinic workflows and 
function in connectivity- challenged and high- volume settings. 
Data collected through the tool should conform to local 
patient privacy regulations and international data standards.
InTroduCTIon
Health workers at primary healthcare (PHC) 
have the greatest challenge of ensuring 
appropriate care for their communities. One 
way to support health workers is through the 
provision of clinical guidance in the form of 
clinical practice guidelines or clinical decision 
support algorithms (CDSAs). Clinical prac-
tice guidelines are a set of recommendations 
on diagnostic and treatment modalities based 
on systematic review of evidence and assess-
ment of the benefits and harms to patients. 
They aim to deliver the best care and rational 
Key questions
What is already known?
 ► Clinical decision support tools deliver evidence- 
based recommendations to support clinical decision- 
making such as prescribing antibiotic treatment.
 ► Although widely integrated in many healthcare ac-
tivities in high- income countries, in low- resource 
settings handheld- based clinical decision support 
algorithms (CDSAs) are being developed and have 
shown to provide benefits to patients (outcome) 
as well as to the public (reduction of antibiotic 
overprescription).
What are the new findings?
 ► To support end user curative and preventive con-
sultations at point of care in low- resource settings, 
stakeholders defined CDSAs that are based on evi-
dence, human- interpretable and customisable to the 
setting and its workflow, and importantly incorporate 
contextual data and diagnostic test performance in 
the patient management recommendation delivered.
What do the new findings imply?
 ► CDSAs can help deliver quality health services by 
providing evidence- based recommendations during 
patient consultations.
 ► The use of such tools, in combination with available 
resources, aims to improve patient outcome and ra-
tional use of diagnostics and therapeutics at point of 
care, and in the long term reduce economic hardship 
on patients and health systems.
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clinical decisions to improve patient outcome. The WHO 
developed several simple clinical decision guidelines to 
support health workers in low- income and middle- income 
countries (LMICs) in the evaluation and management of 
clinical problems, with the ultimate goal of improving 
quality of care.1 These include the Integrated Manage-
ment of Childhood Illness (IMCI) designed in the 1990s 
for common diseases affecting children younger than 
5 years of age,2 which was later adapted for use in the 
community as the integrated Community Case Manage-
ment guideline.3 Other guidelines have been developed 
and either take an integrated management approach 
similar to IMCI, such as the Integrated Management 
of Adolescent and Adult Illness,4 antenatal care (ANC) 
and family planning, or a disease- specific approach (ie, 
WHO’s guidelines for diagnosis, treatment, prevention 
and control of dengue5).
While the global health community awaits updated 
and more comprehensive clinical algorithms, the fourth 
industrial revolution6 is seeing developing economies 
‘leapfrogging’7 mobile technologies across multiple 
sectors, including in health. As a result, a plethora of 
digital clinical decision support systems (CDSS) have been 
implemented in LMICs. CDSS is defined as ‘digitized job 
aids that combine an individual’s health information with 
the health worker’s knowledge and clinical protocols to 
assist health workers in making diagnosis and treatment 
decisions’.8 It is well recognised that adherence to stan-
dardised clinical practice guidelines is a measurement 
of quality of care,9 10 and that improving adherence to 
evidence- based guidelines is associated with better health 
outcomes.11 By digitalising clinical guidelines into elec-
tronic CDSAs, in its simplest form a decision tree, several 
groups have shown significant increase in health worker 
adherence to guidelines compared with routine care (ie, 
CDSA vs paper- based IMCI).12–14
However, today CDSAs carry limitations similar to the 
guidelines and still lack point- of- care (POC) data that 
could improve the accuracy of diagnoses and treatment 
recommendations. In terms of clinical guidelines related 
to febrile illness, the only diagnostic test widely used is 
a malaria rapid diagnostic test (mRDT), and while this 
inclusion was important in the context of ‘test- and- treat’15 
it is limited to ruling in or ruling out one pathogen alone. 
Acute febrile illness can be caused by bacterial or viral 
respiratory infections, or seasonal, geographically local-
ised pathogens like dengue. The inclusion of additional 
simple wet and digital diagnostics into adapted algo-
rithms can reduce antimicrobial overprescriptions as 
well as improve the child’s health outcome.16 17 This was 
demonstrated with IMCI- based CDSAs, and it is postu-
lated that similar benefits on outcome and antimicrobial 
use could be awarded to other use cases.
With the growing development of CDSAs, in partic-
ular those based on widely adapted guidelines that have 
the potential to reach thousands to millions of people, 
including vulnerable groups, it is important to ensure 
that new tools meet the needs of end users. Establishing 
a target product profile (TPP) for such a toolkit is an 
important step towards meeting this goal. TPPs include 
minimal and optimal definitions of the characteristics of 
a proposed health tool to address a defined public health 
need. Ideally the tool is designed to meet the majority 
of optimal characteristic criteria as feasible, while still 
meeting the minimal criteria.
To this end, here we present a TPP that was defined 
through consensus with stakeholders and experts. It 
aims to inform developers and implementers alike of the 
requirements for CDSAs aimed at guiding health workers 
during preventive or curative consultations with any type 
of patient (eg, children, adolescents, adults, pregnant 
women and so on) using, whenever feasible, available 
diagnostic tools.
MeTHods
draft TPP
A draft TPP (version 0) for CDSAs combined with POC 
results was developed (by KGP, SD, RS, ZK, GLM, FGM) 
based on standard procedures at the Foundation for 
Innovative New Diagnostics (FIND) and WHO, where 
characteristics are defined as ‘minimal’ and ‘optimal’ 
criteria (online supplementary file 1). ‘Minimal’ is used 
to refer to the lowest acceptable output for a character-
istic and ‘optimal’ for the ideal target of a characteristic. 
The comment sections in a TPP are used to explain or 
provide examples of the characteristics. As this TPP was 
for a multicomponent toolkit, CDSA and POCs, the struc-
ture of the draft TPP was adapted to cover the different 
components and for the purpose of clarity. These 
sections included general scope, scope of toolkit compo-
nents, electronic clinical decision support algorithm, 
POC tools, app, data and procurement, and were also the 
sections used in the final TPP.
expert meeting
To discuss selected aspects of the draft TPP (algorithm 
validation, performance, machine learning (ML), diag-
nostic data, disease prediction, clinical workflow and 
application functionality) (online supplementary file 
1), a meeting on this subject was convened by FIND and 
WHO involving 39 experts from academic institutions, 
industry, and private and public sectors from 11 coun-
tries.18 Experts were selected based on their experience 
in relevant areas of work directly related to digital health 
(clinical decision support or other digital tools targeting 
resource- challenged settings) and/or diagnostics (wet 
and digital). Following the expert meeting, the TPP was 
updated based on expert feedback (version 1.0) (online 
supplementary file 2).
delphi process
To facilitate consensus building for the TPP, we followed 
a Delphi- like process where TPP version 1.0 was reviewed 
through a three- part online survey. The first part of the 
survey collected professional information from the survey 
respondents, as well as experience with clinical practice/
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research, diagnostic test development, software devel-
opment, implementation of healthcare programmes 
in LMICs and health information systems. The second 
part of the survey allowed for rating of both minimal 
and optimal criteria for all TPP characteristics. Agree-
ment was scored on a Likert scale from 1 to 5, where 1 
corresponds to fully disagree, 2 mostly disagree, 3 neither 
agree nor disagree, 4 mostly agree and 5 fully agree. Disa-
greement with a criterion was based on a rating from 1 
to 3 and required a comment/suggestion by the survey 
respondent. To reach consensus, more than 75% of 
survey respondents should provide a rating of at least 4 
(agreement) on the Likert scale. The third part of the 
survey provided an opportunity for respondents to share 
comments/feedback/ideas on the TPP if not covered in 
the characteristics section. After the first round of the 
survey, agreement for each characteristic was calculated 
as a percentage, and respondent comments, whether asso-
ciated with agreement or disagreement, were reviewed. 
The TPP was revised based on reviewer feedback and sent 
for a second survey. The data were compiled as in the first 
round. If 75% agreement was achieved for all characteris-
tics, the Delphi process was closed.
Patient and public involvement statement
At no point in this work were patients or the public 
involved in the design of this study or in the reporting 
and dissemination of the results.
resulTs
expert consensus on the TPP through a delphi process
In the first round, the online survey was sent to 77 experts 
(including workshop participants), and 28 responded to 
the survey (response rate, 36.4%), with some respond-
ents submitting a coordinated response for their institu-
tion. Twenty- five per cent of the respondents were from 
LMICs (7 of 28); however, the majority of the respond-
ents (22 of 28, 78%) had experience working in Africa 
and 57% (16 of 28) in South- East Asia. More than 85% 
(24 of 28) of the respondents had more than 5 years of 
experience in clinical practice and research, 50% (14 
of 28) in health programme implementation in LMICs, 
39% (11 of 28) in health information systems, 21% (6 
of 28) in software development and 14% (4 of 28) in 
diagnostic product development (online supplementary 
file 3). Most participants work in international organisa-
tions (7 of 28, 25%) and academic institutions (10 of 28, 
35.7%). In the first round, at least 50% agreement was 
reached for all criteria of all the characteristics, and feed-
back was taken into consideration to develop TPP version 
1.1 for the second round of the Delphi survey (online 
supplementary file 4). In this new version, the charac-
teristic ‘Encounter’ was removed as several participants 
expressed it was redundant with the characteristic ‘Work-
flow’. Therefore version 1.1 had 40 characteristics.
A second online survey was sent to the 28 respondents 
from round 1. In this round, 23 participants responded to 
the survey (response rate, 82%). Most participants were 
from academia (7 of 23, 30%), non- profit international 
organisations (7 of 23, 30%) and had a similar profile to 
respondents from round 1 (online supplementary file 3). 
In this round of review, at least 75% of the participants 
agreed with the minimal and optimal criteria for all TPP 
characteristics. On average, 91% of survey respondents 
agreed with the minimal and optimal criteria (figure 1) 
and the TPP was finalised (version 2).
Final TPP
General scope and Scope of toolkit components
This TPP defines a toolkit composed of CDSAs and POCs 
intended to support evidence- based clinical decisions 
made by health workers during a preventive or curative 
consultation, by capturing patient clinical and context- 
specific data, as well as diagnostic test results, to provide 
recommendations on diagnosis and patient manage-
ment (including counselling, follow- up visits and so on). 
The clinical algorithm integrates POC results and is 
embedded in an app. POCs in this toolkit should be regu-
latory approved for use in the setting of implementation.
The experts agreed that the CDSA should first define 
its target: (1) patients (eg, age group), (2) medical prob-
lems (eg, syndrome or disease), (3) end users (eg, mini-
mally trained health worker or trained clinician) and (4) 
level of care (eg, community or health facility) for which 
the clinical recommendations are meant and relevant. 
These specifications should be clearly communicated 
to the end user at the beginning of the algorithm. The 
health worker should immediately be warned if the infor-
mation she or he enters in the system does not fit with 
these specifications. For example, if the scope of a CDSA 
is limited to patients aged 6 months to 5 years and the user 
enters 2 months of age, the CDSA logic should prompt 
an incongruence of the data entry and this should be 
appropriately reported back to the user. In cases where 
an app proposes different algorithms for different use 
cases (ie, ANC, management of childhood illness), the 
specifications shall be clearly available for each individual 
algorithm. For example, if a CDSA allows for consulta-
tions related to ANC for pregnant women as well as for 
neonates, the algorithm should request specific patient 
information to triage patient along different algorithm 
branches respective to the use case (table 1).
Clinical decision support algorithms
Regarding the algorithm’s medical content, the working 
group agreed that it must be evidence- based. Whether 
newly developed or adapted from existing guidelines, 
the algorithm’s medical content should be developed 
following international standards for the development 
or adaptation of evidence- based clinical guidelines, to 
ensure it implements the best available evidence. This 
evidence can originate from well- established clinical 
guidelines such as WHO/international/local clinical 
care guidelines, or from peer- reviewed articles, clinical 
practice and/or validation research, and the level of 
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Figure 1 Figure 1Expert consensus on TPP characteristics.  
Expert agreement is shown for each TPP characteristic minimal (Min) and optimal (Opt) criteria. Agreement was scored on a 
Likert scale from 1 to 5, 1 = fully disagree, 2 =mostly disagree, 3 =neither agree nor disagree, 4 =mostly agree and 5 =fully 
agree. Consensus was reached when more than 75% of survey respondents provided a rating of at least 4. 
CDS, clinical decision support; POC, point- of- care; API, application programming interface
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Table 1 Minimal and optimal target product profile characteristics focused on the general scope of the toolkit and toolkit 
component characteristics, as defined by expert consensus process
General Scope
Characteristics Minimal requirements Optimal requirements Comments
Intended use The toolkit, composed of an electronic clinical decision support 
algorithm(s) and POC diagnostic tests, is intended to increase 
evidence- based treatment decisions by capturing diagnostic test 
results, patient clinical data (eg, exposures, signs including vital signs) 
and context- specific data (eg, disease incidence, seasonality) to 
provide treatment and care recommendations
  
Target population The algorithm shall define the target population
Inclusion and exclusion criteria are used at the encounter to enrol the 
patient
The system can be modular, that is, 
composed of discrete algorithms, such 
that one can be used for a specific 
population based on predefined criteria
Setting (level of 
implementation in the 
healthcare system)
Defined by the algorithm The system can be modular, that is, 
composed of discrete algorithms, such that 
one can be used for a specific healthcare 
setting based on the infrastructure, 
workforce knowledge and skills, and POC 
tools available
Targeted end user Defined by the algorithm The end user shall have the required 
training/skills to use the app appropriately
Scope of toolkit components
Algorithm access The electronic clinical decision support algorithm is accessible through 
an app downloaded on compatible target devices
The app can be a web app, a native app or 
a hybrid app
Algorithm content Built on:
 ►  Well- established clinical evidence based on WHO/international/
local clinical care guidelines, peer- reviewed articles (systematic 
reviews, original clinical research) and clinical experience/practice
 ►  And/or appropriate clinical validation research*
*See FDA’s SaMD clinical evaluation for 
guidance20
Algorithm treatment 
recommendations
Therapeutic recommendations shall 
be compliant with national treatment 
guidelines and national EML, and 
support antimicrobial stewardship
Same as minimal, and 
evidence- based medicine to 
support optimal treatment 
recommendations
Recommendations support the appropriate 
selection, dosage and duration of 
antimicrobial and any other kind of 
treatment and management, causing the 
least harm to the patient
Compatible POC tools POCs or other relevant medical devices 
prompted for use by the app shall be 
locally relevant, that is, recommended 
by EDL or relevant national equivalent 
or country programme
Same as minimal, plus 
emerging diagnostic tools 
and medical devices 
relevant to the algorithm and 
implementation setting
  
Regulated toolkit 
components
POC diagnostic tests and medical 
devices are regulatory approved and 
compliant with local regulations
Same as minimal, and if the 
software is a medical device 
the app shall also have 
regulatory approval
  
Compatible devices The app is compatible with any device, including:
 ►  Smartphones
 ►  Tablets
 ►  Computers
Computers are included as it may be 
necessary for health facility supervisors to 
access data collected at the facility level 
to make informed decisions (ie, restocking 
medical supplies)
Compatible operating 
systems
OS agnostic Same as minimal   
EDL, Essential Diagnostics List; EML, Essential Medicines List; FDA, Food and Drug Administration; OS, operating system; POC, point- of- care; 
SaMD, software as a medical device.
evidence and the strength of recommendations in the 
target context should ideally be communicated. In line 
with this, recommendations should cause the least harm 
to the patient and to the community. For example, algo-
rithms related to treatment and management of a patient 
suffering from infectious diseases should also support 
antimicrobial stewardship to avoid unnecessary side 
effects for the patient and the development of resistance 
in the community and at the global level. In addition, 
the algorithm should be validated both analytically and 
semantically to ensure that the algorithm output is accu-
rate and reproducible, does not deviate from expert 
content/evidence, and that there are no interactions or 
conflicts in the logic.
Furthermore, important characteristics were content 
quality, ML. With the rise of ML also in this domain of 
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Table 2 Minimal and optimal target product profile characteristics focused on the electronic clinical decision support 
algorithm and POC tools, as defined by expert consensus process
Clinical decision support algorithm
Characteristics Minimal requirements Optimal requirements Comments
Content transparency The algorithm is ‘human 
interpretable’. The healthcare 
programme and end user can 
comprehend the algorithm 
decision- making processes
The healthcare programme 
and end user have access 
to underlying evidence and 
methodology used to develop 
the algorithm
Human- interpretable: a human can understand the 
choices taken by the model in the decision- making 
process, that is, how output variables are generated 
based on input variables. Visual representations 
(eg, decision trees, principal component analyses, 
protocol charts and so on) and performance metrics 
can be used to support content transparency
Quality control The algorithm has been (1) analytically and (2) semantically 
tested:
1.  Analytical verification: the algorithm output is accurate 
and reproducible
2.  Semantical verification: the algorithm does not deviate 
from expert content/evidence and there are no interactions 
or conflicts in the logic
(1) and (2) answer the question ‘did I build the model 
right?’
(See FDA’s SaMD clinical evaluation for current 
guidance20)
Algorithm validation The algorithm has been validated. The level of validation will 
depend on the CDSS status as an SaMD
Refer to upcoming rulings from regulatory bodies such as the 
FDA or the European Commission
Answers the question ‘did I build the right model?’
(See FDA’s SaMD clinical evaluation for current 
guidance20)
Machine learning None, the algorithm is static ML is applied to generate 
data on the algorithm 
performance, improve 
content, inform healthcare 
system processes and so on
Changes in the algorithm 
based on ML shall be 
validated
  
POC tool
POC data inputs Any kind of data (qualitative data such as positive/negative/
invalid lateral flow test results, and quantitative data such as 
data provided by haemoglobinometers and glucometers)
  
Disease likelihood Based on:
 ► Pretest probability (in the 
absence of POC or POC 
performance data)
 ► Or POC positive/negative 
likelihood ratio
Based on:
 ►  Pretest probability
 ►  And POC positive/
negative likelihood ratio
The test performance (eg, likelihood ratio) is known 
and performance data ideally previously determined 
through independent studies in relevant settings
The test brand should ideally also be considered so 
as to account for changes between manufacturers
POC training On- site training performed by local authority or implementer   
CDSS, clinical decision support system; FDA, Food and Drug Administration; ML, machine learning; POC, point- of- care; SaMD, software as a 
medical device.
CDSAs to analyse the data captured through algorithms 
and then for example augment algorithm diagnostic 
or prognostic accuracy, workshop experts thought it 
important to address this in the TPP. It was agreed that 
an algorithm that recommends treatment decisions 
and management of patients should be at a minimum 
human- interpretable, meaning one should understand 
how input data are processed into output data. Changes 
to the algorithm logic based on ML analyses should also 
be validated (table 2).
POC tools
POC tools are defined here as medical diagnostic 
resources that can be used by health workers immedi-
ately at point of care to measure clinical parameters (ie, 
vital signs, host biomarkers and pathogen biomarkers) or 
visualise a patient’s tissue. They vary in design complexity 
(lateral flow vs table- top instrument), reagent, ease of use 
and cost. These tools are often budgeted and resourced 
by ministries of health but may not always be available in 
facilities, in particular at lower levels of the healthcare 
system. Using these tools during patient consultations 
and incorporating their data into the algorithms are 
dependent on their availability and whether the CDSA 
was designed to compute those data into triage or recom-
mendation outputs. Experts agreed that the post- test 
probability or the likelihood of a disease being present 
should be assessed based on the pretest probability—that 
is, the prevalence of the disease in the corresponding 
patient population; and the diagnostic positive/negative 
likelihood ratio—that is, how good a test predicts the 
presence or absence of disease, of all clinical information 
(ie, signs, symptoms and POC results) (table 2). Clin-
ical diagnosis often lacks accuracy, and therefore diag-
nostic tests that have the proven added value for patient 
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management should be integrated within algorithms if 
the setting allows for it. These tests can be wet diagnostics 
such as pathogen- specific rapid diagnostic tests or hand-
held devices such as haemoglobinometers, and do not 
exclude digital diagnostics such as digital thermometers.
App
An important characteristic in this section is system 
validation. Today, there is no standard process to vali-
date and assess the performance accuracy of CDSAs. 
There is also a severe lack of evidence and peer- reviewed 
publications on both the development and the perfor-
mance of these tools in LMICs. While some groups 
have performed randomised controlled trials (RCTs) 
to measure patient outcome and other parameters that 
impact patient health, such as the reduction of antibiotic 
overprescription,16 17 others have assessed the perfor-
mance of their tool by measuring health worker adher-
ence to guidelines.12–14 The level of validation ultimately 
depends on the type of algorithm. The US Food and 
Drug Administration has provided some guidance on 
the kind of evidence that needs to be provided.19 The 
TPP criteria are inspired by this guidance. The minimal 
criteria guarantee that the app has a CDSA that is based 
on evidence (clinical association) and that input data are 
processed correctly (analytical validation). The optimal 
criteria include clinical validation, in addition to clinical 
association and analytical validation. Through clinical 
validation, the app has been assessed for the intended 
outcome (ie, improved clinical outcome, better quality 
of care, rational use of resources, reduction of antibiotic 
overprescription and so on) (table 3).
In May 2017, a new regulation (EU 2017/745) on 
medical devices, to which CDSA pertains by definition,20 
was adopted by the European Commission, which will be 
applied starting Spring 2020.21 This regulation includes a 
reinforcement of the rules on the clinical evidence that 
should be provided by developers and manufacturers, 
at least if based in Europe. While waiting for LMICs 
to have their own regulations, this new regulation will 
certainly impact development and validation by Euro-
pean developers.
Experts also called for application programming 
interface to allow other software to ‘talk to’ and interact 
with the tool through commonly known programming 
languages. The app should be protected by authorisation 
and authentication that, as a minimum requirement, 
adhere to usual technical standards, and optimally would 
adhere to the HIE (Health Information Exchange) and/
or HL7 (Health Level Seven) international22 standards. 
It was noted that adherence to HL7 can be expensive; 
hence, this was proposed as an optimal rather than a 
minimal requirement. The app should also be designed 
to integrate with patient care pathways and health worker 
workflows with limited disruption. The app accordingly 
has pause and resume capability to allow time for diag-
nostic tests to be performed and the results entered in the 
algorithm. POCs such as mRDTs can require up to 20 min 
for results to be read, depending on the manufacturer.
Data
Digital tools have the potential to amass enormous 
amount of data. With CDSA, patient personal data are 
captured, stored and potentially used for other oper-
ational (ie, supply chain management) and algorithm 
development purposes. Many countries have personal 
data privacy and protection laws in place to protect citi-
zens from the abuse of their personal information. In 
the European Union this is known as the General Data 
Protection Regulation (GDPR).23 However, there are 
still many countries around the world that do not have 
a national eHealth strategy or personal data legisla-
tion. This called for the need to address personal data 
handling with CDSA for security and accountability 
purposes. Experts agreed that the implementer, who 
would be considered the data controller, is responsible 
for the data and should comply with local data policies 
and legislations. No specific legislation was mentioned as 
this differs by country and region. In addition, the history 
of the processes that are applied to data as well as the 
origin of data should be documented (data provenance). 
The app should function under secure connectivity to 
avoid loss and corruption of sensitive data, and mitigate 
cyberattacks, whether data are at rest or in transmission 
(table 4).
dIsCussIon
In this work, our aim was to develop a TPP to enable 
the development of a toolkit that includes CDSAs that 
are based on evidence and designed to integrate the 
results of the diagnostics performed at point of care to 
guide rational clinical decisions. The use of such toolkit 
would aid in strengthening healthcare particularly at the 
community and primary care echelons, and help address 
health worker difficulties in differentiating diseases and 
syndromes without diagnostic tests and the aid of formal-
ised diagnostic processes, which can be provided through 
algorithms.
In terms of TPP characteristics, ‘Data’ and ‘Validation’ 
emerged as key topics of discussion. Data generated from 
CDSA require storage and connectivity and are therefore 
vulnerable to abuse, loss or unlawful purposes. Although 
many countries have enacted personal data protection 
legislation, many fall short on enforcing these and others 
are still drafting bills. For example, in the African region, 
in 2017, 17 (out of 54) African countries had put in place 
comprehensive personal data protection legislation.24 
Several regimes in the region are starting to draft legis-
lation on processing and movement of personal data25; 
however, funding attrition and the lack of regulators 
cripple the process. That said, there are continent- wide 
initiatives that promise to set data protection frame-
work, such as the EU’s GDPR. The African Network of 
Personal Data Protection Authorities, a cooperation of 
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Table 3 Minimal and optimal target product profile characteristics focused on app characteristics, as defined by expert 
consensus process
App
Characteristics Minimal requirements Optimal requirements Comments
System validation The app has been validated in the 
intended implementation setting. 
There is evidence demonstrating:
 ► Valid clinical association (clinical 
output based on input data is 
supported by well- established or 
novel evidence)
 ► And analytical validation (input 
data are processed correctly into 
expected output data)
The app has been validated in the 
intended setting. There is evidence 
demonstrating:
 ► Valid clinical association (clinical 
output based on input data is 
supported by well- established or 
novel evidence)
 ► And analytical validation (input 
data are processed correctly into 
expected output data)
 ► And clinical validation (clinical 
safety or other meaningful 
outcome relevant to the intended 
use)
There is evidence that the 
system is based on evidence 
and working to achieve the 
intended use for the intended 
setting
(See FDA’s SaMD clinical 
evaluation for current 
guidance20)
System access (public 
API)
Publicly available API for data 
access protected by authentication 
and authorisation. At a minimum, 
technical standards are adhered to
Optimally, HIE/HL7 standards are 
adhered to
  
Context configuration  ►  Language: UN official languages
 ►  Local time
 ►  Local weights and measures
Same as minimal, and the following:
 ►  Option to customise to local 
official language
 ►  Other country preferences
Language can be a major 
barrier to the proper use of the 
tool for patient management 
and can lead to errors and 
misinterpretation
Customisation Changes to the app, such as updates 
to the list of medicines and POCs 
available in the setting, can be 
made by the healthcare programme. 
Validation of this change shall be 
provided
Same as minimal   
User access rights Appropriate data access is provided based on specific roles Roles may include data 
manager (facility supervisor) or 
data entry person (nurse)
Expert support None Built- in access to online/remote 
expert advice to assist in patient 
consultation via SMS, audio call and 
video conferencing
  
App training On- site training Same as minimal, and remote 
training and/or remote ‘Train the 
Trainer’
  
Internet availability  ►  Functions offline (allows 
for service delivery and key 
workflows)
 ►  Allows automatic 
resynchronisation
Same as minimal, and trigger alerts 
on user device when data have not 
been synchronised for a long time
Internet connection can be very 
unstable, therefore the tool 
should work in offline mode so 
as to not disrupt the workflow of 
the user
Clinical data entry Manual entry by the operator Same as minimal, plus automatic 
upload of digital data (eg, from 
biosensors, medical devices)
Optimal: this allows external 
integration of other app 
modules, built- in and third- party 
apps and devices
Patient management 
recommendation
Consultation data are summarised 
and actionable recommendations 
provided (eg, treatment, referral, 
home care or follow- up)
Same as minimal, and 
recommendations are integrated in 
EMRs and HIS
  
Navigation Sequential: the user follows a strict 
sequence of data input to reach a 
final recommendation
Non- sequential: the user can 
move in any direction through an 
assessment and change input data 
to reach a final recommendation
  
Continued
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App
Characteristics Minimal requirements Optimal requirements Comments
Workflow requirements 
to enable time- delayed 
POC data input
Ability for a user to perform multiple, 
simultaneous consultations, with 
pause and resume capability, to allow 
clinical and laboratory data entry
Same as minimal, plus ability to 
disable simultaneous workflow 
feature in settings with minimally 
skilled workers
This is particularly relevant 
for implementation in settings 
where testing and clinical 
consultations are performed in 
different locations
Task management Multiple algorithms can be supported simultaneously in one application 
against a common data set
Can accommodate task- shifting 
capability, that is, multiple 
consultations can be opened at 
a time and patient profiles can 
be accessed using preset user 
access rights
Follow- up None Ability to retrieve patient information 
using patient registration 
information
The optimal implies data 
recoverability, also covered in 
the Data section
System malfunction 
protection
System malfunctions are made clear to the user   
Scalability The app shall allow high transaction volumes with complex workflows to 
cover primary care workforce at a national scale
  
Updates and 
versioning
Processes are in place to control any app changes (including algorithm 
version updates) and provide the appropriate and correct update to the 
user
  
API, application programming interface; EMR, electronic medical record; FDA, Food and Drug Administration; HIE, Health Information 
Exchange; HIS, health information system; HL7, Health Level 7; POC, point- of- care; SaMD, software as a medical device; SMS, short 
message service; UN, United Nations.
Table 3 Continued
eight African countries, seeks to draft data protection 
laws, formulate opinions on specific issues and establish 
a consultative framework on data protection. There are 
also regional conventions for data protection and privacy 
that have been enacted, such as the Southern African 
Development Community Model Law26 for the south and 
the Act on Personal Data Protection within the Economic 
Community of West African States for the west.27 Unlike 
their southern and western counterparts, east African 
nations have not adopted similar regional frameworks, 
which can set cross- border and data portability limita-
tions. In addition, some countries’ national laws fall short 
in setting the required safeguards for data privacy breach 
and data portability and lack bodies such as data protec-
tion authorities to enforce these legislations.24 This is 
just the African scenario, but every country and region 
will have their own set of policies. Therefore, the health-
care programme and data controllers have an important 
responsibility to manage the programme in compliance 
with local laws or, where lacking, consult with government 
authorities on which regulation to abide by to foremost 
protect patient rights. The regulation of CDSS is also a 
very contentious topic, and relevant groups will have to 
watch the landscape closely to determine whether their 
tool fits the definition of a software as a medical device 
and what data they will need to generate for regulatory 
approval.
In terms of ‘Validation’, the big question was how to 
ensure CDSAs are safe for use. Developers and imple-
menters should aim for clinical association, analytical 
validation and clinical validation. However, clinical valida-
tion can require significant amount of financial resources 
and time. As an example, e- POCT (electronic point- of- 
care test) was developed in 2014 to incorporate the latest 
scientific evidence to expand the medical content of 
IMCI. Its safety and efficacy were determined in an RCT 
in Tanzanian outpatient clinics.17 However, in 2019, the 
tool has not yet been implemented at scale or evaluated in 
non- controlled settings. Efforts like e- POCT to optimise 
CDSA content and assess its impact on patient health 
outcomes are needed to grow the evidence for CDSA’s 
role in improving patient care. However, providing these 
tools to patients also demands that we put our efforts in 
studies to measure the effectiveness of CDSA while in the 
hands of the end user and in the setting of intended use. 
Indeed, when CDSAs are implemented as part of routine 
practice, there may be factors that affect the overall effec-
tiveness and impact of the tool. These include lack of or 
poor health worker training, lack of connectivity, software 
malfunctions, and poor design, leading to low usability 
and acceptability of the tool by health workers. Cycles of 
evaluation and improvement can be sought to perfect 
these tools in intended settings. In addition, digital data 
obtained from CDSA validation can be used in turn to 
dynamically improve the tool itself, faster than develop-
ment improvements in classic wet diagnostics. CDSAs 
also have the potential to serve as platforms to support 
the evaluation or development of new content or guide-
lines. These can be adapted more quickly to different 
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Table 4 Minimal and optimal target product profile characteristics focused on data characteristics, as defined by expert 
consensus process
Data
Characteristics Minimal requirements Optimal requirements Comments
Data capture Text, numeric, image, audio, video Same as minimal, and GPS, barcode 
and biometric
  
Data validation The system validates data entry to prevent errors that diminish value of the 
data or the outcome
Data ownership Ownership shall be determined by the healthcare programme The healthcare programme is responsible for 
compliance with any country law, policy and regulation
Data storage The healthcare programme shall be 
able to choose the destination of the 
app’s data
Same as minimal   
Data recovery Data can be recovered or the system can be re- established to the desired 
state in the event of interruption or failure
  
Data flow The flow of data shall be determined 
by the healthcare programme
Same as minimal   
Data reporting Data export available from all target 
devices
Prebuilt data reporting, analytics 
and dashboards are available with 
the app
The level of data manipulation, aggregation and 
reporting should be sensitive to the device the app is 
running on, that is, the computer app can be rich in 
functionality, and the mobile app is optimised for data 
collection and exchange only
Data provenance Included Same as minimal Provides origin and processes applied to output data. 
When data are downloaded or shared, the version of 
the model is tagged so it is always clear how the data 
were obtained
Data dictionary Available, referencing standards used (eg, ICD, SNOMED) Ensures indicators reported are uniform across different 
health programmes
Data security and 
privacy
The app operates under secure connectivity which meets data protection 
and regulations of individual countries to avoid loss and corruption of 
sensitive data, and mitigate cyberattacks, whether data are at rest or in 
transmission.
Conforms to national privacy laws. Includes processes such as:
 ►  Two- factor authentication
 ►  Authorisation/access control
 ►  De- identified data
 ►  Data encryption
Encourages GDPR (should no national data security 
policies exist) to ensure a system that:
 ►  Preserves data integrity
 ►  Identifies and mitigates risks
 ►  Provides relevant parties security processes
GPDR, General Data Protection Regulation; GPS, global positioning system; ICD, International Classification of Diseases; SNOMED, Systematized Nomenclature of 
Medicine.
geographies to conform to local policies or support their 
update.
The call for the development of PHC during the 
Declaration of Astana revived the global commitment to 
provide quality health services to all.28 Achieving universal 
health coverage will therefore require that digital health 
interventions are quality- assured and evidence- based. 
Indeed, the WHO has begun developing frameworks to 
create a common digital language and synthesising the 
evidence around emerging mobile- based digital health 
technologies through two recent publications.8 29 These 
resources are meant to guide the global health commu-
nity in assessing digital interventions that will improve 
quality of care, meaning interventions that are safe, effec-
tive, timely, efficient, equitable and people- centred, and 
these include CDSAs.30
Despite best efforts to balance expertise and knowl-
edge as part of the multidisciplinary group to build 
consensus around a multicomponent tool, it is possible 
that some bias was introduced in certain sections due to 
a lack of expert input. A further limitation is that this 
TPP does not address some classic diagnostic charac-
teristics, namely specimen type, performance accuracy 
(ie, sensitivity and specificity), operating conditions (ie, 
humidity and temperature) and cost. Since the tool is 
intended for an unspecified number of use cases due to 
the vastness of public health issues faced in healthcare 
systems, it was deemed expansive to define the multitude 
of different performance combinations. Further, TPPs 
usually include a cost estimate, but we could not estimate 
the cost of such a toolkit because again the use case and 
the setting of use are not fixed. The use of this kit would 
likely require a service delivery model attuned to the 
country of implementation.
ConClusIon
The management of patients in low- resource settings 
with complex epidemiology is extremely challenging 
without clinical algorithms and accurate and portable 
rapid diagnostic tests. The consequences of suboptimal 
quality of care can go even beyond the patient’s health 
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to include public health considerations, such as the 
development of antimicrobial resistance due to overpre-
scribing of medicines. The aim of the proposed TPP is 
to support developers and implementers of these toolkits 
that are designed to guide health workers throughout 
clinical assessments, to give them confidence in clinical 
decisions and actions, whether it is sending a patient to 
a hospital or not, prescribing or not prescribing antibi-
otics, or recommending rehydration at home.
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